TAS1553, a novel class of RNR inhibitor, has robust antitumor activity in murine syngeneic tumor models as a single agent and in combination with anti-PD-1 checkpoint inhibitor

2020 ◽  
Vol 138 ◽  
pp. S58
Author(s):  
H. Fukushima ◽  
T. Sayaka ◽  
Y. Wakako ◽  
H. Takuya ◽  
U. Hiroyuki ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Checkpoint Inhibitor ◽  
Single Agent ◽  
Tumor Models ◽  
Syngeneic Tumor

Abstract 328: Antitumor activity of the oncolytic peptide LTX-315 in syngeneic tumor models

2016 ◽  
Author(s):  
Ketil André Camilio ◽  
Baldur Sveinbjørnsson ◽  
Sylvie Maubant ◽  
Guillaume Serin ◽  
Jean-François Mirjolet ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Tumor Models ◽  
Syngeneic Tumor

Abstract 2669: Antitumor activity of the CMP-001 (TLR9 agonist) alone or combined with immune modulators in syngeneic tumor models

2017 ◽  
Author(s):  
Francis Bichat ◽  
Sylvie Maubant ◽  
Jean-François Mirjolet ◽  
Philippe Slos ◽  
Arthur M. Krieg ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Tumor Models ◽  
Immune Modulators ◽  
Tlr9 Agonist ◽  
Syngeneic Tumor

scholarly journals Abstract 196: Antitumor activity of lenvatinib against acquired resistance tumor to anti-VEGF therapy in mouse syngeneic tumor models

2019 ◽  
Author(s):  
Kenji Ichikawa ◽  
Saori Watanabe Miyano ◽  
Yukinori Minoshima ◽  
Junji Matsui ◽  
Yasuhiro Funahashi
Keyword(s):  
Antitumor Activity ◽  
Acquired Resistance ◽  
Tumor Models ◽  
Anti Vegf ◽  
Syngeneic Tumor
Sign in / Sign up

Export Citation Format

Share Document